2026ODYSSEY TrialStudiesDolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized TrialREAD MORE
2025ODYSSEY TrialStudiesVirological outcomes and genotypic resistance on dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents:a secondary analysis of the ODYSSEY trialREAD MORE
2023DolutegravirODYSSEY TrialStudiesNeuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trialREAD MORE
2023DolutegravirODYSSEY TrialStudiesEffect of dolutegravir on folate, vitamin B12 and mean corpuscular volume levels among children and adolescents with HIV: a sub-study of the ODYSSEY randomized controlled trialREAD MORE
